Sun Life U.S. renews support of National Alliance on Mental Illness with $50,000 donation
'We are grateful for support from Sun Life, as they are ardent supporters of programs that educate communities and help people access care,' said Jessica Edwards, chief development officer, NAMI. 'The H+M program is a valuable resource, and we are pleased to be able to expand its reach to more people.'
H+M helps people better understand the innate connection between mental and physical health, teaching tools and strategies for simple and immediate ways to improve their health. A survey of H+M participants in 2024 showed that 80% reported an increase in knowledge of healthy behaviors. The program has been picked up by NAMI affiliates and NAMI state groups around the country.
'We must eliminate lingering prejudices and stigma, and ensure every person has universal access to mental health support services, whether in a clinical or community setting,' said Dr. Katie Connell, director of Behavioral Health, Sun Life U.S. 'Mental health can impact physical health, just as physical conditions, especially chronic ones, can often lead to poor mental health. It's important that every person understands the connection and has access to the services they need.'
'Community organizations that empower people to take control of their own health are filling critical gaps in the healthcare ecosystem,' continued Dr. Connell. 'The great work by NAMI and others is driving real change by providing people with the knowledge they need to help them achieve overall health and wellness.'
In addition to supporting NAMI, Sun Life supports Hartford Behavioral Health in Conn., through the annual Strikeout for a Cause campaign with the Hartford Yard Goats baseball team. Sun Life is also a vocal advocate for mental health parity in long-term disability insurance, calling for federal legislation to require broad adoption across the market.
To learn more about NAMI, its Hearts + Minds program, and other programs, visit www.nami.org.
Learn more about Sun Life's community partnerships and philanthropic support at www.sunlife.com/us/en/about/our-community-involvement/.
About Sun LifeSun Life is a leading international financial services organization providing asset management, wealth, insurance and health solutions to individual and institutional Clients. Sun Life has operations in a number of markets worldwide, including Canada, the United States, the United Kingdom, Ireland, Hong Kong, the Philippines, Japan, Indonesia, India, China, Australia, Singapore, Vietnam, Malaysia and Bermuda. As of December 31, 2024, Sun Life had total assets under management of C$1.54 trillion. For more information, please visit www.sunlife.com.
Sun Life Financial Inc. trades on the Toronto (TSX), New York (NYSE) and Philippine (PSE) stock exchanges under the ticker symbol SLF.
Sun Life U.S. is one of the largest providers of employee and government benefits, helping approximately 50 million Americans access the care and coverage they need. Through employers, industry partners and government programs, Sun Life U.S. offers a portfolio of benefits and services, including dental, vision, disability, absence management, life, supplemental health, medical stop-loss insurance, and healthcare navigation. Sun Life employs more than 8,500 people in the U.S., including associates in our partner dental practices and affiliated companies in asset management. Group insurance policies are issued by Sun Life Assurance Company of Canada (Wellesley Hills, Mass.), except in New York, where policies are issued by Sun Life and Health Insurance Company (U.S.) (Lansing, Mich.). For more information visit our website and newsroom.
Media contacts
Devon FernaldSun Life U.S.Devon.Portney.Fernald@sunlife.com781-800-3609
Connect with Sun Life U.S.
https://www.facebook.com/SLFUnitedStateshttps://www.linkedin.com/company/sun-life-financial
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
25-07-2025
- Malaysian Reserve
NAMI Statement on Executive Order Targeting Homelessness and Criminalizing Mental Illness
ARLINGTON, Va., July 25, 2025 /PRNewswire/ — Yesterday, the White House released a new Executive Order, 'Ending Crime and Disorder on America's Streets,' which directs federal agencies to make it easier to involuntarily treat people with serious mental illnesses as part of a bid to address homelessness across the United States. While addressing the nationwide homelessness crisis is urgent and necessary, yesterday's executive order promoting institutionalization of people with mental illness raises grave concerns for NAMI and our community. NAMI's Chief Executive Officer Daniel H. Gillison, Jr. said: 'Mental illness is not a crime, and people with mental illness deserve to be treated as human beings, with dignity and respect. While we agree that homelessness is an urgent crisis in our country, to truly address the systemic causes of this crisis, we should be pouring resources into treatment to improve early access to care and investing in supportive housing and other wrap-around services. It's always ideal – and best – for an individual to engage in their own treatment. Yet, too many NAMI families know that isn't always possible. Unfortunately, yesterday's order concerningly focuses broadly on institutionalization and not on real solutions that we know work in helping people lead better lives.' NAMI believes that in the rare instances where voluntary engagement in treatment is not possible, involuntary commitment should be used only as a last resort and only when it is believed to be in the best interests of the individual. While it is unclear how the executive order will be carried out since state law governs the process of involuntary civil commitment, the order also urges moving away from a 'housing first' approach, which has been successful in helping individuals stay connected to treatment and reduce homelessness. While NAMI is troubled by the overall order, it does include a direction to federal agencies to support crisis response services and prioritize funding for mental health and drug courts – strategies that NAMI supports. This executive order comes at a time when significant cuts are being made to mental health services nationwide. Earlier this month, Congress passed legislation that will drastically cut Medicaid and Supplemental Nutrition Assistance Program (SNAP) benefits, impacting millions of Americans. The Administration has rescinded more than $1 billion in grants from the Substance Abuse and Mental Health Services Administration (SAMHSA), with more cuts proposed for the next fiscal year. These changes will result in far too many people being unable to get the treatment they need. When that happens, more people will be arrested, incarcerated, land in emergency rooms, lose their connection to family and community, and ultimately become homeless. NAMI's Chief Advocacy Officer Hannah Wesolowski said: 'Rather than providing access to critical mental health services, this executive order appears to prioritize coercive tactics to move people who are homeless out of the public eye. This does nothing to address the root causes of homelessness, runs a high risk of exacerbating the homelessness crisis, and is not the way to address our mental health needs. People with mental illness deserve better.' For more information on the public policies that NAMI supports, visit
Malay Mail
21-07-2025
- Malay Mail
Shanghai Healthcare M&A Fund Strategically Acquires Chengdu Kanghua Biological, Establishing a Fully Integrated Ecosystem
Shanghai Healthcare M&A Fund Strategically Acquires Chengdu Kanghua Biological HONG KONG SAR - Media OutReach Newswire - 21 July 2025 - Chengdu Kanghua Biological Products Co., Ltd. (Stock Code: announced that Shanghai Healthcare M&A Fund ("the M&A Fund") intends to acquire the Company through a strategic agreement. Leveraging its substantial resource and financial strength, the M&A Fund plans to support Kanghua Biological's established product portfolio, accelerate sales of its mature products, and develop industry synergies between Shanghai and Chengdu. The goal is to rapidly expand a diversified vaccine pipeline and build an integrated vaccine ecosystem that combines proven commercialized products with best-in-class R&D vaccine industry is an essential pillar of public health with high entry barriers, stringent oversight, and extended development cycles – all factors contributing to its significant growth potential. As a leading domestic vaccine producer, Kanghua Biological's flagship product - human diploid cell rabies vaccine – stands as China's first domestically developed premium vaccine with over a decade of safe application, established market presence and nationwide distribution. The Company also maintains a robust global innovation pipeline, having successfully licensed its recombinant hexavalent norovirus vaccine overseas. This strategic acquisition, focused on critical segments of the vaccine value chain, will strengthen its strategic positioning. The M&A Fund is committed to supporting Kanghua Biological in leveraging its core product line while harnessing the combined strengthens of Shanghai and Chengdu to accelerate the formation of a next-generation vaccine industry acquisition marks a significant step to drive Shanghai and Chengdu biopharmaceutical cooperation. Post-transaction, Kanghua Biological will capitalize on Shanghai's advanced R&D resources and access to top-tier scientific talent and global capital to enhances its industrial capabilities, manufacturing capacity, and market penetration. The M&A Fund will consolidate diverse industrial assets to promote Kanghua Biological's integration with Shanghai's R&D and clinical networks, creating an end-to-end collaborative system that spans from "clinical R&D to commercialization" and accelerates the development of a full industrial value chain."This transaction goes beyond a typical corporate acquisition, it represents a transformative catalyst for industrial upgrading,""This exemplifies the complementary strengths created by resource-empowered consolidation. With deep biopharmaceutical, financial, R&D, and global network expertise, Shanghai Healthcare M&A Fund will create significant synergies with Kanghua Biological's technologies, products, manufacturing, and domestic distribution to have an outsized impact on the sector."Hashtag: #SIICCapital #ChengduKanghuaBiological #ShanghaiHealthcareM&AFund The issuer is solely responsible for the content of this announcement. About Shanghai Healthcare M&A Fund A core component of Shanghai's state-owned capital fund network, Shanghai Healthcare M&A Fund is managed by SIIC Capital, a subsidiary of SIIC Group. The M&A Fund targets Shanghai's biopharmaceutical sector, aligning government policy objectives with industrial needs by fostering collaboration with leading industry companies, strengthening sector clusters, and enabling asset restructuring. Through capital infusion, improving governance, optimizing management, and executing M&A, the M&A Fund backs "anchor" companies to build complementary and reinforcing links in the value chain, driving the ongoing transformation of specialized subsectors. About Chengdu Kanghua Biological Products Co., Ltd. Chengdu Kanghua Biological Products Co., Ltd. is a biopharmaceutical company engaged in research, manufacture and commercialization of biological products. Established in 2004, the company operates an in-house testing center and GMP-certified bacterial and viral vaccine production facilities. Its marketed portfolio includes the ACYW135 meningococcal polysaccharide vaccine and a freeze-dried human diploid cell rabies vaccine. Kanghua holds GMP certification from China's National Medical Products Administration, has participated in numerous scientific research projects and has been granted patents for over 100 technologies.
New Straits Times
17-07-2025
- New Straits Times
YSP to ramp up expansion plans, production
KUALA LUMPUR: YSP Southeast Asia Holding Bhd (YSP SAH), one of the top pharmaceutical manufacturers on the FBM KLCI by market capitalisation, is accelerating efforts to grow its presence in both domestic and international markets. Leveraging a combination of offline and online business strategies, the group aims to strengthen its presence in the increasingly competitive pharmaceutical sector. Rashica Lim Yin, head of business development strategy office, e-commerce and consumer healthcare at YSP Industries (M) Sdn Bhd, said the group is committed to growth, underpinned by a strong pipeline of new products and a sustained focus on research and development (R&D). "It's a potential business segment, but also very competitive. That's why we can't rest on our laurels. We must keep innovating and developing products that support the health and wellness of the community," Lim said at the unveiling of the company's latest innovation – the botanical beauty and wellness rituals series by GREENS – during the Greenstopia event in Kuala Lumpur last week. YSP SAH is among the top five pharmaceutical manufacturers in Malaysia. Its operations cover the R&D, manufacturing, warehousing and logistics, and trading of pharmaceutical products ranging from prescription medications and OTC (over-the-counter) remedies to consumer healthcare products, including traditional and complementary medicines. As part of its growth strategy, the company is sharpening its focus on exports, particularly within Asean markets, where demand for affordable quality healthcare products continues to rise in line with expanding private healthcare expenditure across the region. Asked whether current global economic headwinds have impacted operations, Lim said it remains "business as usual" for the company, supported by steady demand for affordable medicines and ongoing product innovation. YSP SAH continues to channel significant investment into R&D to fuel its product pipeline. The group's latest launch – the botanical beauty and wellness rituals series – is an example of this commitment. Lim noted that development for this latest innovation took three years, with its key raw materials sourced from Japan and South Korea. "We are very bullish about the potential of this product and the e-commerce exclusive GREENS series. Patented and clinically proven ingredients supported the product development that we use. We also did extensive market studies to validate demand and growth prospects," she added. Greenstopia, now running in its third year, combines community recycling initiatives with health education and wellness activities. Each Greenstopia edition, including the latest Greenstopia 3.0, encourages attendees to exchange recyclable items such as plastic, aluminium, paper, e-waste and clothing for fresh produce and refreshments, fostering both environmental awareness and community bonding, in line with the GREENS branding vision of creating products that are as close to nature and eco-friendly as possible and with sustainable sources. With a clear strategy to expand its domestic and export markets and a renewed push in health and wellness innovation, YSP SAH is positioning itself to capture new opportunities in an evolving healthcare landscape while reinforcing its standing as one of Malaysia's top pharmaceutical players.
